A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögren
Sjogren Disease
Sjogren's Syndrome

Interventions

DRUG: CLN-978

Sponsor

Cullinan Therapeutics Inc.